Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/27790
Title: Molecular and genomic characterisation of a panel of human anal cancer cell lines.
Austin Authors: Guerra, Glen R;Kong, Joseph C;Millen, Rosemary M;Read, Matthew;Liu, David Shi Hao ;Roth, Sara;Sampurno, Shienny;Sia, Joseph;Bernardi, Maria-Pia;Chittleborough, Timothy J;Behrenbruch, Corina C;Teh, Jiasian ;Xu, Huiling;Haynes, Nicole M;Yu, Jiaan;Lupat, Richard;Hawkes, David;Di Costanzo, Natasha;Tothill, Richard W;Mitchell, Catherine;Ngan, Samuel Y;Heriot, Alexander G;Ramsay, Robert G;Phillips, Wayne A
Affiliation: Centre for Cancer Research, The University of Melbourne, Parkville, VIC, 3010, Australia
Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia
Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia
Department of Biochemistry and Pharmacology, The University of Melbourne, Parkville, VIC, 3010, Australia
VCS Foundation, Carlton, VIC, 3053, Australia
Department of Pathology, University of Malaya, Kuala Lumpur, Malaysia
Department of Surgery, St Vincent's Hospital, The University of Melbourne, Parkville, VIC, 3010, Australia
Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia
Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia
The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, 3010, Australia
Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, 3010, Australia
Surgery
Issue Date: 18-Oct-2021
Date: 2021-10-18
Publication information: Cell Death & Disease 2021; 12(11): 959
Abstract: Anal cancer is a rare disease that has doubled in incidence over the last four decades. Current treatment and survival of patients with this disease has not changed substantially over this period of time, due, in part, to a paucity of preclinical models to assess new therapeutic options. To address this hiatus, we set-out to establish, validate and characterise a panel of human anal squamous cell carcinoma (ASCC) cell lines by employing an explant technique using fresh human ASCC tumour tissue. The panel of five human ASCC cell lines were validated to confirm their origin, squamous features and tumourigenicity, followed by molecular and genomic (whole-exome sequencing) characterisation. This panel recapitulates the genetic and molecular characteristics previously described in ASCC including phosphoinositide-3-kinase (PI3K) mutations in three of the human papillomavirus (HPV) positive lines and TP53 mutations in the HPV negative line. The cell lines demonstrate the ability to form tumouroids and retain their tumourigenic potential upon xenotransplantation, with varied inducible expression of major histocompatibility complex class I (MHC class I) and Programmed cell death ligand 1 (PD-L1). We observed differential responses to standard chemotherapy, radiotherapy and a PI3K specific molecular targeted agent in vitro, which correlated with the clinical response of the patient tumours from which they were derived. We anticipate this novel panel of human ASCC cell lines will form a valuable resource for future studies into the biology and therapeutics of this rare disease.
URI: https://ahro.austin.org.au/austinjspui/handle/1/27790
DOI: 10.1038/s41419-021-04141-5
ORCID: 0000-0002-2505-1643
0000-0001-5003-0433
0000-0002-7961-638X
Journal: Cell Death & Disease
PubMed URL: 34663790
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

20
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.